AKRO
Akero Therapeutics Inc

2,290
Loading...
Loading...
News
all
press releases
LLY Gets EU Approval for Alzheimer's Drug & FDA Nod to Cancer Therapy
Eli Lilly secures EU approval for Alzheimer's drug Kisunla and gains FDA nod to breast cancer therapy Inluriyo.
Zacks·2h ago
News Placeholder
More News
News Placeholder
Zacks Industry Outlook Highlights Halozyme Therapeutics, Akero Therapeutics, Kiniska Pharmaceuticals, ANI Pharmaceuticals and Twist BioScience
Biotech stocks gain momentum as M&A, AI-driven drug discovery, and new approvals fuel growth; Halozyme, Akero, Kiniska, ANI and Twist stand out.
Zacks·2d ago
News Placeholder
CRSP & Sirius Begin Dosing in Thromboembolic Disorder Study in EU
CRISPR Therapeutics and Sirius dose the first patient in a phase II study of SRSD107 for thromboembolic disorders in Europe.
Zacks·3d ago
News Placeholder
5 Biotech Stocks Worth Adding to Your Portfolio Now
New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position HALO, AKRO, KSNA, ANIP and TWST in this volatile sector
Zacks·3d ago
News Placeholder
NTLA Completes Enrollment in Pivotal Study on HAE Candidate, Stock Up
Intellia shares surge nearly 30% as the company completes enrollment in its pivotal phase III HAELO study on lonvo-z for hereditary angioedema.
Zacks·7d ago
News Placeholder
Krystal Biotech Stock Up on FDA Nod to Vyjuvek Label Update
KRYS shares jump after the FDA expands Vyjuvek's label to include DEB patients from birth, with added at-home use flexibility.
Zacks·10d ago
News Placeholder
Is Boston Scientific (BSX) Outperforming Other Medical Stocks This Year?
Here is how Boston Scientific (BSX) and Akero Therapeutics, Inc. (AKRO) have performed compared to their sector so far this year.
Zacks·11d ago
News Placeholder
FDA Accepts Corcept's NDA for Relacorilant in Ovarian Cancer
CORT's NDA for relacorilant in platinum-resistant ovarian cancer gains FDA acceptance, with a decision expected by July 2026.
Zacks·15d ago
News Placeholder
IONS Up on FDA's Breakthrough Tag for ION582 in Angelman Syndrome
Ionis jumps as FDA grants Breakthrough Therapy status to ION582 for treating Angelman syndrome, with the phase III study now underway.
Zacks·16d ago
News Placeholder
AQST Stock Up as FDA Skips Advisory Meeting to Discuss Anaphylm NDA
Aquestive Therapeutics shares surge after FDA skips advisory meeting on Anaphylm NDA, keeping its January 2026 action date intact.
Zacks·21d ago

Latest AKRO News

View

Advertisement|Remove ads.

Advertisement|Remove ads.